BIIB Stock Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$213.57|
|52 Week High||US$372.12|
|52 Week Low||US$187.16|
|1 Month Change||3.57%|
|3 Month Change||-0.64%|
|1 Year Change||-37.24%|
|3 Year Change||-9.31%|
|5 Year Change||-21.63%|
|Change since IPO||6,826.60%|
Recent News & Updates
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|BIIB||US Biotechs||US Market|
Return vs Industry: BIIB underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: BIIB underperformed the US Market which returned -18.4% over the past year.
|BIIB Average Weekly Movement||5.0%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: BIIB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BIIB's weekly volatility (5%) has been stable over the past year.
About the Company
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.
Biogen Fundamentals Summary
|BIIB fundamental statistics|
Is BIIB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIIB income statement (TTM)|
|Cost of Revenue||US$2.39b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||9.90|
|Net Profit Margin||13.40%|
How did BIIB perform over the long term?See historical performance and comparison
Is BIIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIIB?
Other financial metrics that can be useful for relative valuation.
|What is BIIB's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does BIIB's PE Ratio compare to its peers?
|BIIB PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
BMRN BioMarin Pharmaceutical
GILD Gilead Sciences
UTHR United Therapeutics
Price-To-Earnings vs Peers: BIIB is good value based on its Price-To-Earnings Ratio (21.6x) compared to the peer average (112.9x).
Price to Earnings Ratio vs Industry
How does BIIB's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: BIIB is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the US Biotechs industry average (15.4x)
Price to Earnings Ratio vs Fair Ratio
What is BIIB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||21.6x|
|Fair PE Ratio||23x|
Price-To-Earnings vs Fair Ratio: BIIB is good value based on its Price-To-Earnings Ratio (21.6x) compared to the estimated Fair Price-To-Earnings Ratio (23x).
Share Price vs Fair Value
What is the Fair Price of BIIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIIB ($213.57) is trading below our estimate of fair value ($468.21)
Significantly Below Fair Value: BIIB is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: BIIB is poor value based on its PEG Ratio (9.4x)
Discover undervalued companies
How is Biogen forecast to perform in the next 1 to 3 years based on estimates from 29 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIIB's forecast earnings growth (2.3% per year) is above the savings rate (1.9%).
Earnings vs Market: BIIB's earnings (2.3% per year) are forecast to grow slower than the US market (13.9% per year).
High Growth Earnings: BIIB's earnings are forecast to grow, but not significantly.
Revenue vs Market: BIIB's revenue (0.1% per year) is forecast to grow slower than the US market (8.4% per year).
High Growth Revenue: BIIB's revenue (0.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIIB's Return on Equity is forecast to be low in 3 years time (15.8%).
Discover growth companies
How has Biogen performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIIB has a large one-off loss of $1.2B impacting its March 31 2022 financial results.
Growing Profit Margin: BIIB's current net profit margins (13.4%) are lower than last year (23.9%).
Past Earnings Growth Analysis
Earnings Trend: BIIB's earnings have declined by 4.9% per year over the past 5 years.
Accelerating Growth: BIIB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BIIB had negative earnings growth (-51.9%) over the past year, making it difficult to compare to the Biotechs industry average (96.9%).
Return on Equity
High ROE: BIIB's Return on Equity (13.7%) is considered low.
Discover strong past performing companies
How is Biogen's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BIIB's short term assets ($7.9B) exceed its short term liabilities ($3.9B).
Long Term Liabilities: BIIB's short term assets ($7.9B) do not cover its long term liabilities ($8.4B).
Debt to Equity History and Analysis
Debt Level: BIIB's net debt to equity ratio (31.4%) is considered satisfactory.
Reducing Debt: BIIB's debt to equity ratio has increased from 56.8% to 64.8% over the past 5 years.
Debt Coverage: BIIB's debt is well covered by operating cash flow (41.7%).
Interest Coverage: BIIB's interest payments on its debt are well covered by EBIT (12.7x coverage).
Discover healthy companies
What is Biogen current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIIB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIIB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BIIB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michel Vounatsos (59 yo)
Mr. Michel Vounatsos serves as Director at PerkinElmer, Inc. since March 1, 2020. He has been the Chief Executive Officer and Director of Biogen Inc. since January 6, 2017. Mr. Vounatsos served as the Chie...
CEO Compensation Analysis
Compensation vs Market: Michel's total compensation ($USD17.69M) is above average for companies of similar size in the US market ($USD13.43M).
Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.
Experienced Management: BIIB's management team is considered experienced (4.7 years average tenure).
Experienced Board: BIIB's board of directors are seasoned and experienced ( 12.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biogen Inc.'s employee growth, exchange listings and data sources
- Name: Biogen Inc.
- Ticker: BIIB
- Exchange: NasdaqGS
- Founded: 1978
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$31.278b
- Shares outstanding: 146.45m
- Website: https://www.biogen.com
Number of Employees
- Biogen Inc.
- 225 Binney Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.